Amycretin (zenagamtide)

Used for

• Weight loss
• Type 2 diabetes (studied)

How it works

GLP-1 and amylin both signal fullness and slow the stomach; here they come from a single molecule instead of two drugs. The newer papers also list calcitonin receptor activity.

What the research shows

• Weekly injection, phase 1b/2a (125 people, one US center, up to 36 weeks): 60 mg lost 24.3% vs 1.1% on placebo at week 36, 20 mg 22.0%, 5 mg 16.2% at week 28 and 1.25 mg 9.7% at week 20. Many people dropped out, mostly for reasons unrelated to side effects; stomach side effects were common.
• Daily pill, first-in-human (144 people): doses up to 50 mg a day; 62% had a side effect, all mild or moderate and mostly stomach-related.
• Phase 2 in type 2 diabetes (36 weeks): the weekly injection lowered HbA1c 0.9% (0.4 mg) to 1.7% (40 mg); the pill lowered it 0.9%, 1.3% and 1.4% on 6, 25 and 50 mg.

Dosing

Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.

Side effects

• Nausea, especially after a dose step
• Constipation or diarrhea
• Reflux, burping
• Lower appetite and thirst: dehydration risk

Cautions

• Not for anyone with a personal or family history of medullary thyroid cancer or MEN2.
• Pancreatitis and gallbladder problems are uncommon but reported; severe belly pain needs urgent care.
• Rapid weight loss costs muscle too: keep protein high and keep lifting.
• Stop before planned surgery or sedation per your doctor (slower stomach emptying).
• Only early, small trials so far: long-term safety is unknown.

Storage

More in Weight & metabolic